Patent Application
20220236283
This application claims priority to EP 20171823.6, filed on Apr. 28, 2020, and EP 21154080.2, filed on Jan. 28, 2021, the disclosures of which are incorporated herein by reference in their entireties.
The present invention relates to analytical methods for identifying and quantifying complex glycoconjugate compositions, particularly to the analysis of a polysaccharide component of a glycoprotein in a sample. The invention further relates to the use of liquid chromatography-mass spectrometry systems (“LC-MS systems”) in such analytical methods, particularly to the use of LC-MS systems for in-process control during glycoconjugate manufacturing, for release control of produced glycoconjugates, for stability control of stored glycoconjugates and for process-optimization of glycoconjugate manufacturing.
There is an increased pressure of regulatory authorities on biopharmaceutical manufacturers to demonstrate satisfactory programs for understanding, measuring, and controlling glycosylation in glycoprotein-based drugs. However, the analysis of complex glycoconjugate compositions, i.e. identification and absolute quantification thereof, is a challenging task. Such analysis typically comprises a number of assays and requires for full analysis under GMP conditions 1 week or even longer.
For glycoprotein-based drugs, the state-of-the art chemical assays are performed on high-performance liquid chromatography systems (HPLC systems) equipped with different detectors: For determination of total and free polysaccharides (PS), a pulsed amperometric detector is used which requires laborious sample preparation by hydrolyzing the sugar chains and detecting the released monosaccharides after ion chromatography separation. As stated by ThermoFisher Scientific, a manufacturer of such HPLC systems, “Carbohydrates are difficult to analyze using common chromatography and detection method” but their “electrochemical detection has been optimized for carbohydrate analysis” (1). Conclusively, amperometric detection and quantification may be considered the gold standard in carbohydrate quantification. However, one of the technique's main disadvantage (required monosaccharides) makes sample preparations of glycoprotein-based drugs laborious and release assays time- and cost-intensive.
Additionally, all glycoprotein-based drugs undergo further analytical release testing (e.g. free glycans in the drug substances, glycan modifications) besides the general release arsenal for purity and identity requested by regulatory authorities. These multiple different release criteria result in long release times for glycoprotein-based drugs.
Mazsaroff et al. (2) describe analysis of carbohydrate structures of glycoproteins using LC-MS systems and In-Source fragmentation. The document describes an analytical method for relative quantification by determining the ratio of two peaks. As explicitly stated by the authors, it is “important to understand that the fragment ion peak area ratio at optimum conditions for signal-to-noise ratio might not reflect the absolute ratio of the fragment ions present in the glycoprotein molecule investigated, but the optimum conditions yield the best measure for relative quantification of fragment ion ratio in the comparison of the different batches of a biopharmaceutical product to its standard.” Conclusively, the document fails to describe any absolute quantification of carbohydrate structures; nor does it suggest the use of a reference material calibration curve.
Ivancic et al. (3) describe the LC-MS analysis of complex multiglycosylated human a1-acid glycoprotein as a model for developing identification and quantification methods for intact glycopeptide analysis. The document describes an analytical method where in-source fragmentation is used to fragment carbohydrates, which are used as markers to identify glycopeptides. The technique ultimately aims to quantify the “degree of glycosylation” of a peptide in the AAG-protein. This means the comparison of peak intensities of peptides identified to be glycosylated to peak intensities of non-glycosylated peptides. Again, the document fails to describe any absolute quantification of carbohydrate structures; nor does it suggest the use of a reference material calibration curve.
Carell et al. (US 2020/041470) (4) discloses a derivatisation reagent for polysaccharides as a component of glycoproteins. The use of this derivatisation reagent and isotopologues thereof in combination with a calibration curve that is generated from a reference material enables the absolute quantification of such polysaccharides by LC-MS systems that are capable of fragmenting selected ions by collision-induced dissociation (CID). As derivatisation of the analyte is a pre-requisite for quantification, the document fails to describe any LC-MS method wherein the glycoprotein is in its native state. Such derivatisation of the polysaccharide component requires the addition of a sample preparation step in comparison to a method that analyzes a glycoprotein in its native state, and thus renders such methods inevitably more cumbersome. Furthermore, the method requires the use of a sophisticated LC-MS system in which specific ions resulting from the in-source fragmentation can be selected and further fragmented by CID. Such sophisticated equipment is not only more expensive per se but also validation of a corresponding analysis method is more time-consuming than methods without such requirements. The use of a relatively simple LC-MS system and a protocol that requires a minimum of handling steps is thus regarded beneficial, particularly in the context of a drug release assay.
Echeverria et al. (5) describe an MS method for quantifying glycans which are part of a monoclonal antibody. Absolute quantification of the polysaccharides is achieved after cleavage from the antibody by incubation with the enzyme PNGase F. For quantification, a mix of isotopically labelled glycans is added to the sample as an internal standard and analysis is performed by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS. Again, this document fails to describe any analysis method for glycoproteins wherein the glycoprotein is in its native state. Further, the method does not use liquid chromatography to separate the glycoproteins within the sample prior to MS analysis but merely suggests the possibility of applying the reported mix of isotopically labelled glycan standards to LC-MS based methods. As discussed above, addition of a sample preparation step, e.g. PNGase F mediated release of the PS component from the carrier protein, renders the analysis method more cumbersome and thus reduces the throughput in comparison to a method that does not involve such a step.
Furthermore, PNGase F digestion is not applicable to all polysaccharide structures, thus limiting the method of the prior art to glycoproteins that are within the substrate specificity of PNGase F.
Similarly, Jeong et al. (6) describe a MALDI-TOF MS method for the absolute quantification of glycans after their PNGase F mediated release from a glycoprotein, followed by permethylation of the glycans. Hence, this document also does not describe a quantification method for glycoproteins wherein the glycoprotein is in its native state. The described method also does not include LC-based separation of the glycoproteins prior to MS analysis. As outlined above, addition of a sample preparation step renders the analysis method more cumbersome and reduces the throughput. In this particular case, sample preparation does not only involve PNGase F digestion (thereby inherently putting a limitation on the method) but also includes a permethylation step, thus further complicating sample preparation.
In consequence, there is a need for improved analytical methods for glycoconjugates, particularly glycoprotein-based drugs.
Thus, it is an object of the present invention to mitigate at least some of these drawbacks of the state of the art.
In particular, it is an aim of the present invention to provide analytical methods which bypass the sample preparation thereby increasing the analytical throughput, and also decreasing release costs, for glycoprotein-based drugs.
Further, it is an aim of the present invention to provide analytical methods combining multiple different release criteria in one assay thereby further reducing batch release time of glycoprotein-based drugs.
In particular, it is an aim of the present invention to provide analytical methods that simultaneously provide information on identity and absolute quantity of glycoprotein-based drugs.
One or more of the above objectives are achieved by an analytical method as defined in claim 1 and the use of LC-MS systems as defined in claim 12. Further aspects of the invention are disclosed in the specification and independent claims, preferred embodiments are disclosed in the specification and the dependent claims.
The present invention will be described in more detail below. It is understood that the various embodiments, preferences and ranges as provided/disclosed in this specification may be combined at will. Further, depending of the specific embodiment, selected definitions, embodiments or ranges may not apply.
The present invention will be better understood by reference to the figures.
As visible in
Unless otherwise stated, the following definitions shall apply in this specification:
As used herein, the term “a”, “an”, “the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
As used herein, the terms “including”, “containing” and “comprising” are used herein in their open, non-limiting sense. It is understood that the various embodiments, preferences and ranges may be combined at will.
Throughout this specification a number of abbreviations are used, including:
AUC Area Under the Curve
CID collision induced dissociation, an MS technique
EPA detoxified Exotoxin A of P. aeruginosa
ETD electron transfer dissociation, an MS technique
HPLC high performance liquid chromatography,
IC-PAD Ion Chromatography-Pulsed Amperometric Detection
ISF In-Source fragmentation
LC liquid chromatography
LPS lipopolysaccharide
MS mass spectrometry
PS Polysaccharide
RP Reverse Phase
SEC Size Exclusion Chromatography
TIC Total Ion Current, an MS technique
The above abbreviations, and further abbreviations mentioned in the specification, are common in the field.
The term “glycoconjugate” is known in the field and particularly describes chemical entities covalently bound to one or more polysaccharide(s). Such glycoconjugate may be obtained by biological conjugation in a living cell (“bioconjugate” or “biological conjugate”) or may be obtained by chemical conjugation of a polysaccharide (“chemical” or “synthetic” glycoconjugate). Suitable chemical entities include proteins/peptides and lipids, the corresponding glycoconjugates being glycoproteins, (including proteoglycans, peptidoglycans and glycopeptides) and glycolipids.
The term glycoprotein includes “traditional glycoproteins” and “glycoconjugate vaccines”. In traditional glycoproteins, the emphasis is on the protein part, such as for instance for antibodies or erythropoietin where the ‘active’ principle is more residing in the protein part, and the glycans play a role for instance in half-life or defining other properties. Such traditional glycoproteins find widespread use in pharmaceutical applications. In glycoconjugate vaccines, the emphasis is on the glycan part, to which an immune response is desired because the glycans are the relevant antigens, and the protein part merely serves as a carrier to lead to a desired T-cell memory immune response.
The term glycoprotein further includes “proteoglycans” and “peptidoglycans” and “glycopeptides”. The term “proteoglycans” refers to proteins that are heavily glycosylated. The basic proteoglycan unit consists of a core protein with one or more covalently attached glycosaminoglycan (GAG) chain(s). The point of attachment is a serine (Ser) residue to which the glycosaminoglycan is joined through a tetrasaccharide bridge. The term “peptidoglycan” refers to a polymer consisting of saccharides and amino acids that form a mesh-like layer outside the plasma membrane of most bacteria, forming the cell wall. The term “glycopeptide” refers to a glycoprotein comprising up to 50 amino acids in the protein part. Such glycopeptide being available e.g. via digestion of a larger glycoprotein (e.g. via trypsin digestion), bacterial fermentation or chemical synthesis.
The term “glycolipids” is known in the field and particularly describes entities where one or more saccharide(s) are linked by a glycosidic (covalent) bond to a lipid. Consequently, the characterizing feature of a glycolipid is the presence of a saccharide (particularly a polysaccharide as discussed herein) bound to a lipid moiety.
The term “polysaccharide” is known in the field and particularly describes polymeric carbohydrates composed of monosaccharide units bound together by glycosidic linkages, either linear or branched. Such polysaccharides are characterized by their repeating units, each repeating unit described with their respective monosaccharide composition. Said repeating units include one or more monosaccharides which can also be chemically modified (e.g. amidated, sulphonated, acetylated, phosphorylated, etc). Typically found monosaccharides in said repeating units are cyclic or linear monosaccharides containing three to seven carbon atoms. In the specific case of glycoconjugate vaccines, the conjugated polysaccharide originates from a pathogenic species (e.g. Escherichia coli) with said repeating unit defined by the genetics of the specific pathogen. The repeating unit can thus be a specific marker/identifier of the pathogen.
The term “polysaccharide component” consequently denotes one or more glycan chain(s) of a glycoconjugate. Glycans can be monomers or polymers of sugar residues, but typically contain at least three sugars, and can be linear or branched. A glycan may include natural sugar residues (e.g., glucose, N-acetylglucosamine, N-acetyl neuraminic acid, galactose, mannose, fucose, arabinose, ribose, xylose, etc.) and/or modified sugars (e.g., 2′-fluororibose, 2′-deoxyribose, phosphomannose, 6′-sulfo N-acetylglucosamine, etc). The term “glycan” includes homo- and heteropolymers of sugar residues. The term “glycan” also encompasses a glycan component of a glycoconjugate (e.g., of a glycoprotein, glycopeptide, glycolipid). The term also encompasses free glycans, including glycans that have been cleaved or otherwise released from a glycoconjugate.
The term “O-acetylated polysaccharide”, as used herein, refers to polysaccharides where one or more monosaccharides of the repeating unit are chemically modified by acetylation. Said monosaccharides have one or more of their present hydroxyl groups acetylated. For pathogen-derived repeating units used in glycoconjugate vaccines, the O-acetylation of certain monosaccharides can be essential to induce an immune response for said pathogen. Examples of pathogen-derived polysaccharide components are shown in Table 1.
The terms “glycan”/“glycan chain” are synonyms of “polysaccharide” as defined below. Correspondingly, in the context of this invention, “glycan” and the prefix “glyco-”, also refers to the carbohydrate portion of a glycoconjugate, such as a glycoprotein or a glycolipid.
The term “serotype” as used herein, refers to glycoconjugates having different polysaccharide chains which are derived from different bacterial serotypes. Examples of glycans from a number of E. coli serotypes are identified below in Table 1.
The term “native state” is known in the field and relates to a biomolecule, such as a glycoconjugate, in its intact and functional state. When referring to native state within the invention, native state means that the glycoconjugate to be analysed is not derivatised or otherwise modified during sample preparation, for example with an enzyme such as PNGase F, or subjected to a chemical reaction. Analysis of a glycoconjugate in its native state thus differs from any method that involves derivatisation of the glycoconjugate or that involves a sample preparation step to release the glycans from the carrier molecule, e.g. a carrier protein, prior to subjecting the sample to the LC-MS step of the analysis. However, when referring to native state within the invention, the term native state does not relate to the conformation of the glycoconjugate, i.e. its three-dimensional fold such as its secondary structure, tertiary structure or quaternary structure. “Analysis of a glycoprotein in its native state” is thus meant to be synonymous with “analysis of a glycoprotein, wherein the glycoprotein is neither subjected to (i) enzymatic digestion with an enzyme that removes the polysaccharide component from the carrier protein nor to (ii) a chemical reaction, e.g. derivatisation, in each case prior to introducing the glycoprotein into the LC-MS system”.
In more general terms, in a first aspect, the invention relates to a method for analysing a polysaccharide component (a glycan) of a glycoconjugate in a sample. It is important to note that such analysis refers to both, the identification of said polysaccharide component, and the absolute quantification of said polysaccharide component. The inventive method comprises the steps of (a) establishing a calibration curve of said polysaccharide component by means of an LC-MS system; (b) measuring the sample on the same LC-MS system; (c) comparing the results of (a) and (b) to thereby analyse said polysaccharide component in said sample. In an advantageous embodiment, the glycoconjugate is a glycoprotein.
In a preferred embodiment, the glycoconjugate, preferably a glycoprotein, is in its native state. Hence, as no enzymatic release, e.g. PNGase F mediated release, of the PS component from the carrier protein is required, the method is also applicable to the analysis of glycoconjugates that are not susceptible to such enzymatic cleavage, e.g. glycoconjugates comprising sugar motifs that are not within the substrate specificity of PNGase F such as sugar motifs comprising N-acetylglucosamine (GlcNAc) linked to an alpha 1,3-fucose. As outlined in further detail below, the inventive method provides information on at least two and preferably more, most preferably all, of
(i) identity of polysaccharides in,
(ii) absolute quantity of polysaccharide bound to another chemical entity of the glycoconjugate, such as protein, in,
(iii) quantity of free polysaccharide in,
(iv) quantity and identity of modifications such as acetylation in bound and free polysaccharide in, and
(v) purity of, samples containing glycoconjugates, particularly glycoprotein-based pharmaceutical compositions. This aspect of the invention, particularly the process steps and terms used, shall be explained in further detail below:
Glycoconjugate: The term is discussed above. The inventive method is broadly applicable and may be used for analyzing glycoproteins (including proteoglycans, peptidoglycans and glycopeptides) and glycolipids.
Glycoprotein: The term is discussed above. Specifically, it relates to a conjugation product wherein a polysaccharide (i.e. a glycan) is covalently coupled to a carrier protein. The conjugate can be a bioconjugate, which is a conjugation product prepared in a host cell, wherein the host cell machinery produces the glycan and the protein and links the glycan to the carrier protein, e.g., via N-links of asparagine or arginine. The conjugate can also be prepared by chemical linkage of the protein and glycan chain, e.g. via thiol alkylation. The inventive method is applicable to all types of conjugation. Without being bound to theory, it is believed it is not relevant how the sugar is attached, as long as it is fragmented in-source by the MS. Whether or not fragmentation does occur at the protein-glycan-interface, this is not relevant, as the reference material will show the same fragmentation.
Particularly useful glycoconjugates include carrier proteins to which one or more polysaccharides are attached. Such glycoconjugates are for instance used as the active components of certain vaccines, which aim at inducing functional immune responses against the polysaccharides of the glycoconjugates. In embodiments of the invention, said glycoprotein comprises one carrier protein and one or more polysaccharides covalently bond to said carrier protein, preferably 1 to 4 polysaccharides covalently bound to said carrier protein.
In embodiments of the invention, the glycoprotein is a conjugation product containing an E. coli O-antigen covalently bound to a carrier protein. The term O-antigen is known in the field and used in its normal context; it is not to be confused with O-linked. The term O-antigen generally refers to a repetitive glycan polymer contained within an LPS of a bacteria, such as E. coli. The O-antigen of E. coli is a polymer of immunogenic repeating oligosaccharides (typically 1-40 repeating units) and typically used for serotyping and glycoconjugate vaccine production.
Carrier Protein: In embodiments of the invention, the carrier protein is selected from the group consisting of detoxified Exotoxin A of P. aeruginosa (EPA), E. coli flagellin (FliC), CRM197, maltose binding protein (MBP), Diphtheria toxoid, Tetanus toxoid, detoxified hemolysin A of S. aureus, clumping factor A, clumping factor B, E. coli heat labile enterotoxin, detoxified variants of E. coli heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, E. coli Sat protein, the passenger domain of E. coli Sat protein, Streptococcus pneumoniae Pneumolysin, Keyhole limpet hemocyanin (KLH), P. aeruginosa PcrV, outer membrane protein of Neisseria meningitidis (OMPC), and protein D from non-typeable Haemophilus influenzae.
In a particular embodiment, the carrier protein is a detoxified exotoxin A of Pseudomonas aeruginosa (EPA). In such embodiments, the EPA preferably comprises 1 to 20, preferably 1 to 10, preferably 2 to 4, glycosylation sites.
In a particular embodiment, the EPA comprises four glycosylation sites. See for example WO 2017/035181 for a description of examples of bioconjugation of E. coli O-antigen polysaccharides to EPA carrier protein.
Polysaccharide: The term is discussed above. Suitable polysaccharides comprise 1 to 100, such as 1-50, 1-40, 1-30, 1-20, and 1-10, 3-50, 3-40, e.g. at least 5, such as 5-40, e.g. 7-30, e.g. 7 to 25, e.g. 10 to 20, e.g. 5-20, repeating units n. Such repeating units contain (i.e. comprise or consist of) (i) non-modified mono-saccharides and/or (ii) modified monosaccharides. The term “modified mono-saccharides” particularly relates to chemically modified mono-saccharides and in non-limiting embodiments includes N-acetylation, O-acetylation, amidation and/or amination of mono-saccharides. Such modified mono-saccharides may comprise one or more modifications, particularly one, two or three of the above modifications, at the same mono-saccharide.
In embodiments of the invention, suitable repeating units comprise mono-saccharides selected from the group consisting of Mannose, Rhamnose, Glucose, Fucose, Galactose, modified Mannose, modified Rhamnose, modified Glucose, modified Fucose, and modified Galactose.
Non-limiting and exemplary structures of E. coli O-antigen polysaccharides are shown below in Table 1. A single repeating unit for each E. coli O-antigen polysaccharide is shown. In this table, each n is independently an integer of 1 to 100, such as 1-50, 1-40, 1-30, 1-20, and 1-10, 3-50, 3-40, e.g. at least 5, such as 5-40, e.g. 7-30, e.g. 7 to 25, e.g. 10 to 20, e.g. 5-20, but in some instances can be 1-2.
E. coli O-antigen Polysaccharide
Sample: The term sample is known in the field. It includes any material which, optionally after dilution, may be supplied to an analytical system. Such sample particularly include (i) production batches of glycoconjugate production (including in-process batches and released/stored production batches); (ii) compositions comprising multiple glycoconjugates, such as pharmaceutical compositions comprising a multivalent vaccine. Suitable samples comprise, in addition to the glycoconjugate, (i) an aqueous matrix; (ii) optionally carrier protein free of polysaccharides (or free peptide in case of glycopeptides; or free lipid in case of glycolipids), (iii) optionally polysaccharides not bound to carrier protein (or peptide, or lipid, herein: “free PS”), (iv) optionally non-related proteins (or peptides, or lipids). The aqueous matrix (i) may contain one or more of buffers (e.g. phosphate buffer), inorganic salts (e.g. NaCl), sugar alcohols (e.g. D-Sorbitol), non-ionic surfactants (e.g. Polysorbate 80). The non-related proteins (iv) may include up to 10%, up to 50% or even up to 90% process related impurities (e.g. host cell proteins). It is considered particularly beneficial that the inventive method is tolerant to a wide variety of additional components in the sample. It is thus suitable to analyse a sample without laborious preparation and containing materials that are otherwise interfering to standard analytical protocols.
In an embodiment, the sample comprises one single glyco-conjugate.
In a further embodiment, the sample comprises a multitude of glycoconjugates, such as 2-20, e.g. 4-10 glyco-conjugates. Again, glycoconjugates preferably relates to glycoproteins. The inventive method therefore also allows analysis of complex samples comprising a multitude of glycoconjugates, e.g. having glycans from multiple serotypes. Thus, even complex samples for release of a drug product, such as a multivalent conjugate vaccine, may be analysed by the inventive method. It is apparent that the inventive method advances production of drug products comprising a multitude of serotypes and improves quality and safety of such complex drug products.
It is apparent that the inventive method is also suited to verify the absence of glycoconjugates, e.g. blank samples, and hence in certain embodiments a sample comprises no glycoconjugate.
In one embodiment, the sample comprises one carrier protein or carrier peptide. In another embodiment, the sample comprises more than one carrier protein or carrier peptide. The inventive method is therefore suited to analyze samples comprising multiple different glycoproteins/glycopeptides, not only comprising different glycosylation patterns of the same carrier protein/peptide, but also differing in the carrier protein/peptide. The term carrier protein/peptide thus refers to one single carrier protein/peptide as outlined above and also to a multitude of carrier proteins/peptides, such as 2-10, e.g. 2-5 different carrier proteins/peptides being present in a sample.
Analytical method: The method according to the invention allows for the identification and absolute quantification of total polysaccharide component content in a sample. Furthermore, the method of the invention is able to differentiate between the amount of bound and free polysaccharides in the sample. Accordingly, in one embodiment, the invention provides for a method for identifying and quantifying the bound and free polysaccharides content in a composition comprising at least one glycoconjugate. Furthermore, the method of the invention is able to confirm the absence of a polysaccharide component (bound and/or free PS) in a sample.
As discussed above, the inventive method comprises 3 steps: (a) calibrating; (b) measuring; (c) identifying and quantifying the polysaccharide component of a glycoconjugate, wherein preferably the glycoconjugate is in its native state. These steps shall be explained in further detail below and are further illustrated in the examples in the figures provided:
Step (a), establishing a calibration curve of the polysaccharide component by means of an LC-MS system: To prepare a calibration curve, aliquots of a reference material are subjected to an LC-MS system. The reference material is a sample with known identity and known absolute amount of said polysaccharide component(s). Such reference material may be obtained by subjecting a sample comprising the polysaccharide component to a conventional analytical protocol.
In an embodiment of the invention, step (a) includes the preparation of a reference material and calibrating an LC-MS system with said reference material. The preparation of a reference material may be accomplished according to steps a1-a3 and optionally a4-a5 as outlined below. Calibration of a reference material may be accomplished according to step a6 as outlined below.
Step (a1): This step comprises determination of identity of said glycoprotein in the reference material. Suitable analytical methods are known per se and include, for example, Western Blot electrophoresis or MS.
Step (a2): The following step comprises determination of total polysaccharide (PS) content of said glycoprotein in the reference material. Suitable analytical methods are known per se and include, for example, IC-PAD after hydrolysis.
Step (a3): The following step comprises determination of free PS content in the reference material. Suitable analytical methods are known per se and include, for example, IC-PAD after hydrolysation and separation of bound and non-bound PS.
Step (a4): The following optional step comprises determination of the degree of modification (in specific embodiments the modification is O-Acetylation) of said glycoprotein. Suitable analytical methods are known per se and include, for example, ion chromatography IC-CD after removal of modifying groups (e.g. release of O-Acetyl groups by hydrolysis).
Step (a5): The following optional step comprises determination of purity of said glycoprotein in the reference material. Suitable analytical methods are known per se and include, for example, RP-HPLC and/or SEC.
Following steps (a1 . . . a3) and optionally (a4 . . . a5) a reference material is obtained comprising the polysaccharide component of a glycoprotein. Aliquots thereof are prepared for the following step (a6). Such aliquots of the reference material contain polysaccharide component in known concentration, i.e. in a known absolute amount.
Step (a6): This step includes measuring of aliquots of the reference material by means of an LC-MS system. The data obtained (including retention time, peak identification, AUC determination) allow to establish a calibration curve. In this step, the reference material is separated via LC first, the eluate is subjected to In-Source fragmentation (ISF) inside the MS detector by adapting the ionisation voltage (cone voltage). It is understood that step a6 is performed after aliquots of the reference material are obtained. Such calibration curve being specific to the LC-MS system and the parameters used.
As outlined above, the glycoprotein is preferably in its native state. However, in alternative embodiments, it is possible to digest the glycoprotein with a peptidase, e.g. with trypsin, prior to subjecting the sample to the LC-MS step of the analysis. Such digestion with a peptidase, e.g. trypsin, only leads to cleavage of peptide linkages but does not result in cleavage of a sugar-peptide bond. In case of glycoprotein-containing samples, such digestion leads to the generation of glycopeptides that are subjected to the LC-MS step of the analysis. In that case, the reference material is digested before performing step (a6) and the sample is digested before performing step (b1). The resulting glycopeptides may still be regarded as being in a native state, i.e. neither subjected to (i) enzymatic digestion with an enzyme that removes the polysaccharide component from the carrier protein nor to (ii) a chemical reaction, e.g. derivatisation, in each case prior to introducing the sample into the LC-MS system. Digestion of glycoproteins with a peptidase, e.g. treatment with trypsin, is known to the skilled person.
In preferred embodiments of the invention, the sample is not digested with an enzyme, such as a peptidase.
Step (b), measuring the sample on the same LC-MS system: Measuring a sample on a LC-MS system is known per se, it includes (b1) providing a sample to the LC-MS system and (b2) measuring the sample on the LC-MS system.
It is apparent to the skilled person that the calibration of step (a) may be used for measuring of one single sample in step (b) or for measuring a multitude of samples in step (b). Thus steps (b1) and (2) may be performed repeatedly for measuring a multitude of samples. For example, 2 samples from the same serotype, are measured with the same calibration curve by providing the first sample (b1) and measuring the first sample (b2) followed by providing the second sample (b1′) and measuring the second sample (b2′). Thus measuring a sample includes measuring a single sample and measuring a multitude of samples.
Step (b1): Samples may be provided to the LC-MS system in any known manner. Typically, the injection from a vial comprising the sample into the system by way of an autosampler is chosen. The sample may be directly obtained from a manufacturing batch. The sample may be diluted to match with a concentration range of the calibration curve. In case of glycoprotein-containing samples, the sample is preferably in its native state.
In alternative embodiments, such sample may be digested with a peptidase, such as trypsin, to subject the glycopeptides for analysis. As discussed above, the resulting glycopeptides may still be regarded as being in a native state, i.e. neither subjected to (i) enzymatic digestion with an enzyme that removes the polysaccharide component from the carrier protein nor to (ii) a chemical reaction, e.g. derivatisation, in each case prior to introducing the sample into the LC-MS system. Thus, in methods according to the invention, the sugar-peptide bonds are not cleaved prior to subjecting the sample to the LC-MS step of the analysis.
In that alternative embodiment, the reference material is digested as well before performing step (a6).
In preferred embodiments of the methods of the invention, the sample is not digested with a peptidase, nor with any enzyme. Methods without enzymatic digestion have the advantage to make the analysis much simpler.
Step (b2): According to the inventive method, the sample is measured with the same parameters as in step (a6) above. Preferably, the sample is measured on the same LC-MS system which was used for preparing the calibration curve. Preferably, the sample is measured within 8 hours after the calibration curve is established. All these measures improve data quality; they are known to the skilled person and consider the sensitivity of LC-MS systems towards external factors.
In a first embodiment, the measuring of the sample includes
This allows to determine the absolute quantity of the glycan chain.
In a second embodiment, the measuring of the sample includes
This allows to additionally determine the degree of acetylation in the sample.
In a third embodiment, the measuring of the sample includes
In a fourth embodiment, the measuring of the sample includes
In a fifth embodiment, the measuring of the sample includes
This allows to additionally determine the (relative or absolute) amount of non-conjugated glycan.
In a sixth embodiment, the measuring of the sample includes
This allows to additionally determine the amount (relative or absolute) of non-conjugated glycan also considering the degree of bound acetylated PS.
In a seventh embodiment, the measuring of the sample includes
This allows to additionally determine the amount of free acetylated PS.
In an eighth embodiment, the measuring of the sample includes
In a ninth embodiment, the measuring of the sample includes
In a tenth embodiment, the measuring of the sample includes
Thus, in embodiments of the invention, the simultaneous determination of the identity of the sample and one or more of the following is achieved: PS content, acetylated PS content, free PS content, free acetylated PS content and purity of the sample. Notably, simultaneous determination of the identity of the sample and the following parameters is usually not possible in case of methods that involve a sample preparation step to release the glycans from the carrier molecule, e.g. a carrier protein, or that involve derivatisation of the glycoprotein (additional impurity introduced): free PS content, free acetylated PS content and purity of the sample.
In other embodiments, the method for the analysis of a polysaccharide component of a glycoprotein in a sample regarding the aspects outlined in the first-tenth embodiment comprises the steps of: (a) establishing a calibration curve of said polysaccharide component by means of an LC-MS system, wherein this step (a) includes
the preparation of a reference material (steps a1-a3 and optionally a4-a5) and calibrating an LC-MS system with said reference material (step a6) and wherein the calibration curve is established by separation of the aliquots of said reference material via LC, and subjecting the eluate of the LC to in-source fragmentation inside the MS detector by adjusting the ionisation voltage; (b) measuring the sample on the same LC-MS system using the same parameters as in step a (a6) with the same LC-MS system; (c) comparing the results of (a) and (b) to thereby analyse said polysaccharide component in said sample. Notably, further fragmentation, e.g. using CID or ETD is not required. Thus, in an embodiment, the invention as described herein provides a method, where no additional fragmentation of the ion that is obtained after in-source fragmentation, is required.
In an embodiment, the invention provides a method as described herein, where no internal standard is added to the sample. In order to provide reliable results, it was found sufficient to generate a separate calibration curve. It is regarded beneficial that it is not required to use an internal standard as omitting it reduces handling steps and thus simplifies the method.
The purity of a sample may be determined in a known manner, e.g., via refractive index detector, via UV detector, of the LC part of the LC-MS system. Alternatively, or in addition, the purity may be determined by the MS. This may be done by looking at the total ion current.
Step (c), comparing the results of (a) and (b) to thereby analyse the polysaccharide component in the sample: Until now, LC-MS systems were not used for absolute quantification of a polysaccharide component in a glycoconjugate against a calibration curve. Accordingly, step (c) includes (c1) identification of characteristic peaks for each PS in the sample and (c2) comparing the Area Under the Curve (AUC) for such peak with the calibration curve. It is apparent to the skilled person that in embodiments where the measurement of a sample in step (b) was repeated for a multitude of samples (e.g. of the same serotype, or including the same glycoprotein) as described above, step (c) may likewise be repeated for each sample, using the same calibration curve.
In a second aspect, the invention relates to the use of a liquid chromatography-mass spectrometry system (“LC-MS system”) to analyse a polysaccharide component of a glycoconjugate in a sample. In a preferred embodiment, said glycoprotein is in its native state. The above definitions, such as “sample”, “glycoconjugate”, “polysaccharide”, “carrier protein”, and “native state” are likewise applicable to this second aspect of the invention. Particularly, the term “glycoconjugate” includes the meaning of “glycoprotein” and more specifically of a “carrier protein to which one or more polysaccharides are attached”. This aspect of the invention shall be explained in further detail below:
Analysis: Again, it is important to note that said analysing includes both, the identification of said polysaccharide component, and the absolute quantification of said polysaccharide component. Identification of a PS component includes confirmation of presence and confirmation of absences of said PS component. Thus, if it is expected a specific PS component being present in the sample, e.g. as the sample stems from a production batch, the identification of said PS component is the confirmation of its presence. Likewise, it may be expected that a specific PS component being absent in a sample, which can be confirmed as well. Absolute quantification of said PS component includes determination of concentration measured e.g. in μg [PS-component]/mL [Sample].
In embodiments, the invention also relates to the use of an LC-MS system for in-process control in the production of glycoconjugates, particularly for in-process control in the production of glycoconjugate vaccines.
In embodiments, the invention also relates to the use of an LC-MS system for release control of produced glycoconjugates, particularly for release control in the production of glycoconjugate vaccines. Thus, the LC-MS system may be used as a release assay for a drug substance or a drug product; said drug substance or drug product comprising one or more glycoconjugates, particularly one or more glycoconjugate vaccines.
In embodiments, the invention also relates to the use of an LC-MS system for stability control of stored glycoconjugates, particularly for stability control of stored glycoconjugate vaccines. Thus, the LC-MS system may be used as an assay for shelf life of a drug substance or a drug product; said drug substance or drug product comprising one or more glycoconjugates, particularly one or more glycoconjugate vaccines.
In embodiments, the invention also relates to the use of an LC-MS system for process-optimisation in the development of glycoconjugate manufacturing, particularly glycoconjugate vaccines manufacturing. Using an LC-MS system as described herein significantly simplifies identification of critical parameters and thus allows faster development and shortens timelines during scale-up.
LC-MS system: HPLC systems connected to a mass spectrometric detector are commonly referred to as LC-MS systems. These detectors are capable to determine the molecular mass of a specific analyte present in a sample. Their precision and mass accuracy are often referred to as the gold standard for determining molecular masses of molecules.
A known side effect of analyzing glycoconjugates, such as glycoproteins, on a LC-MS system is the fragmentation of the glycan when injecting the sample into the detector. This effect is called “In-Source fragmentation” (ISF) and related to the voltage applied during injection (the so-called “cone voltage”). ISF is not ideal for a well performing MS detector as it can lead to unknown/unidentifiable ion fragments in complex samples. Therefore, suppliers test for low ISF during system performance qualification (<2%).
In the MS-field, ISF is commonly known and for glycan occupancy testing not desirable as it can completely remove the glycan modification from the remaining part of the conjugate (e.g. the peptide chain from a glycopeptide). On the other hand, sugar fragmentation is performed to further identify and characterize monosaccharide composition by reporter ions. However, this fragmentation usually requires much higher energy and therefore different MS-techniques (CID, ETD).
The inventors have surprisingly found that glycoconjugates subjected for LC-MS analysis display the effect of ISF, which separates the glycan repeating unit, clearly visible as a distinct peak of the corresponding mass (
In an embodiment, the LC-MS system is an LC-MS system with in-source fragmentation of the eluate obtained from the liquid chromatography. Such systems are commercially available, e.g. from Waters Corporation, Sciex, ThermoFisher Scientific.
In an embodiment, the LC-MS system further comprises a divert valve in front of the MS detector. Such valve allows diverting only a fraction of the eluate into the MS detector. Again, such systems are commercially available.
In embodiments, the glycoprotein is as defined above, it particularly comprises one carrier protein and one or more polysaccharides covalently bound to said protein. In certain embodiments the sample comprises more than one carrier protein, each carrying one or more covalently bound polysaccharides.
In embodiments, the carrier protein is as defined above. For example it is selected from the group consisting of detoxified Exotoxin A of P. aeruginosa (EPA), E. coli flagellin (FliC), CRM197, maltose binding protein (MBP), Diphtheria toxoid, Tetanus toxoid, detoxified hemolysin A of S. aureus, clumping factor A, clumping factor B, E. coli heat labile enterotoxin, detoxified variants of E. coli heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, E. coli Sat protein, the passenger domain of E. coli Sat protein, Streptococcus pneumoniae Pneumolysin, Keyhole limpet hemocyanin (KLH), P. aeruginosa PcrV, outer membrane protein of Neisseria meningitidis (OMPC), and protein D from non-typeable Haemophilus influenzae. In a particular embodiment, the carrier protein is a detoxified exotoxin A of Pseudomonas aeruginosa (EPA).
In embodiments, the polysaccharides are as defined above. For example, the polysaccharides comprise 1-100, such as 5-20 repeating units. Exemplary structures are shown in Table 1, above.
In embodiments, the sample further comprises an aqueous matrix; optionally carrier protein (or lipid or peptide) free of polysaccharides; optionally polysaccharides not bound to carrier protein (or lipid or peptide); and optionally non-related proteins.
The following list of references provides additional information in the context of the present invention. These documents are incorporated by reference.
To further illustrate the invention, the following examples are provided. These examples are provided with no intend to limit the scope of the invention.
A glycoprotein sample in larger quantities is directly obtained from a manufacturing batch and is aliquoted and stored appropriately (e.g. −80° C.). The different characterization steps are performed on thawed aliquots of said glycoprotein sample.
1) Determine the correct identity of the reference material. A standard western blot protocol is followed using a specific antibody which has been selected and tested for specificity for the polysaccharide chain of the glycoprotein of interest. Optionally, the correct identity of the carrier protein is determined using a specific antibody for the carrier protein.
2) Determine the total polysaccharide content within the reference material. A total acidic hydrolysis into monosaccharides is performed with subsequent analysis by ion chromatography and pulsed amperometric detection (IC-PAD), according to the following instructions.
Take an aliquot of the reference material and hydrolyse for 2 h at 120° C. using Trifluoracetic acid (TFA) at a final concentration of 1.8 M. Optimal hydrolysis conditions (temperature, TFA concentration and time) may vary depending on the starting concentration of the polysaccharides. Optimal conditions must demonstrate to quantitatively release all the monosaccharides from the polysaccharide chain with no further degradation of the monosaccharide molecule targeted for absolute quantification.
After hydrolysis, cool the sample down to room temperature and then dry it by using a SpeedVac, typically at 30° C. over night. Completely resuspend the dry sample in H2O (MilliQ-grade) and transfer the sample into an HPLC vial. Prepare a set of calibration standards using a commercially available monosaccharide (e.g. Mannose). If the targeted monosaccharide for quantification undergoes modification during the above-mentioned hydrolysis step (e.g. N-Acetylglucosamine is turned into Glucosamine) use the appropriate monosaccharide, or alternatively perform the hydrolysis procedure mentioned-above on the set of calibration standards as well.
Prepare an ion chromatography system (e.g. Dionex ICS-5000) equipped with a pulsed amperometric detector (PAD) which has a disposable gold electrode on Polytetrafluoroethylene (PTFE) installed. Use a Dionex CarboPac PA1 analytical column (4×250 mm) and optionally a Dionex CarboPac PA1 guard column (4×50 mm). Equilibrate the system with Eluent A, 16 mM NaOH for sample elution, and Eluent B, 500 mM NaOH for column cleaning. Sequentially inject the sample and the calibration standard set using the following instrument method/gradient profile:
Depending on the targeted monosaccharide, these gradients may need to be optimized.
Use the area under the curve from the measured calibration set to obtain a calibration curve and then quantify the unknown sample. Optionally, the amount of targeted monosaccharide is then used to back-calculate the absolute amount of repeating units/polysaccharides in μg/mL in the glycoprotein sample.
3) Determine the free polysaccharide content within the reference material. The carrier protein bound polysaccharides are removed by a C4-cartridge, followed by a total acidic hydrolysis into monosaccharides with subsequent analysis by ion chromatography and pulsed amperometric detection. Depending on the size of the glycoprotein, a different carbon polymer length of the cartridge material may be chosen (e.g. C8-cartridge) to completely retain the carrier protein.
Because the sample preparation step is laborious, it is recommended to use an additional monosaccharide not present in the reference material as an internal standard (e.g. Galactose) to compensate for potential sample loss during preparation. Take two aliquots of the reference material and add the same amount of internal standard. Equilibrate a C4 cartridge (e.g. Chromafix C4-SPE from Macherey-Nagel) according to the manufacturer's manual; e.g. 5 column volumes 100% Methanol, then 5 column volumes 100% Acetonitrile, then 5 column volumes 5% v/v Acetonitrile. During the next step, collect the flow through containing the free polysaccharide: Apply one of the two aliquots onto the cartridge and subsequently apply 2 column volumes 5% Acetonitrile. Measure the volume of the collected flow through and add an equal amount of 5% Acetonitrile to the other aliquot, which has not been applied to the C4 cartridge. Dry both prepared samples using a SpeedVac, typically at 30° C. overnight. Completely resuspend both dried samples in H2O (MilliQ-grade) and then follow the procedure mentioned above for total acidic hydrolysis into monosaccharides: Add Trifluoracetic acid (TFA) to a final concentration of 1.8 M to both samples and hydrolyse for 2 h at 120° C. (Optimal hydrolysis conditions may vary and should be optimized). After hydrolysis, both samples are cooled down to room temperature and then dried using a SpeedVac, typically at 30° C. overnight. Completely resuspend both dried samples in H2O (MilliQ-grade) and transfer into HPLC vials.
Prepare an ion chromatography system (e.g. Dionex ICS-5000) equipped with a pulsed amperometric detector (PAD) which has a disposable gold electrode on Polytetrafluoroethylene (PTFE) installed. Use a Dionex CarboPac PA1 analytical column (4×250 mm) and optionally a Dionex CarboPac PA1 guard column (4×50 mm). Equilibrate the system with Eluent A, 16 mM NaOH for sample elution, and Eluent B, 500 mM NaOH for column cleaning. Sequentially inject both prepared samples using the following instrument method/gradient profile:
Depending on the targeted monosaccharide, these gradients may need to be optimized.
Use the area under the curve from the targeted monosaccharide (e.g. Mannose) and the applied internal standard (e.g. Galactose) to normalize the measured areas. The free polysaccharide content of the analysed sample is determined by relatively comparing the normalized areas of the two measured aliquots: The C4-cartridge treated aliquot represents the percentage of free polysaccharides within the sample compared to the non-C4-cartridge treated aliquot which represents 100% of available polysaccharides. Use the obtained value of free polysaccharides to calculate from the above determined total polysaccharide content the amount of “bound polysaccharides”.
4) Determine the degree of modification of the polysaccharide chain in the reference material. This optional step describes the determination of O-Acetylated sugar moieties which uses a mild alkaline hydrolysis followed with subsequent analysis by ion chromatography and conductivity detection. Take an aliquot of the reference material and perform a desalting step to remove free Acetate molecules in the sample (e.g. Zeba Spin column, PD-10 column) by following the manufacturer's manual. Add an internal standard to the desalted sample (e.g. Propionate, 20 μg/mL) and hydrolyse for 2 h at 37° C. using NaOH at a final concentration of 10 mM. Optimal hydrolysis conditions (NaOH concentration, temperature and time) may vary depending on the starting concentration of the polysaccharides. Optimal conditions must demonstrate to quantitatively release all the O-Acetate groups from the polysaccharide chain with no further degradation of the Acetate in the sample.
After hydrolysis, the sample is cooled down to room temperature and then filtered to remove the residual protein which might interfere during HPLC analysis (e.g. centrifugal filter, PES 3 kDa). Follow the manufacturer's manual to prepare the filters and collect the filtrate containing the released Acetate molecules.
Prepare a set of calibration standards using a commercially available Acetate standard for ion chromatography. The calibration standard sets must contain the same amount of internal standard as applied above (e.g. Propionate, 20 μg/mL). Prepare an ion chromatography system (e.g. Dionex ICS-5000) equipped with a conductivity detector and a suppressor installed. Use a Dionex IonPac AS11-HC analytical column (4×250 mm) and optionally a Dionex IonPac AS11-HC guard column (4×50 mm). Equilibrate the system with Eluent A, 1 mM NaOH for sample elution, and Eluent B, 100 mM NaOH for column cleaning. Sequentially inject the sample and the calibration standard set using the following instrument method/gradient profile:
Depending on the ion chromatography system, the suppressor setting may vary.
Use the internal standard to normalize the area under the curve for both, the measured calibration set and the unknown sample. Then use the obtained calibration curve to quantify the Acetate concentration in the unknown sample. The degree of O-acetylated monosaccharide can be calculated by determining the ratio of Acetate per determined polysaccharide content (as described above).
5) Optionally, determine the relative purity of the reference material. This is achieved by size exclusion chromatography and/or reverse phase chromatography. Select an appropriate column for the targeted glycoprotein (e.g. Supelco TSKgel G3000SWXL for size exclusion, Cosmosil 5C4-AR-300 for reverse phase) and perform the chromatography step according to the manufacturer's manual. For example, measured absorbance at 215 nm can be used to determine the glycoprotein's relative purity compared to other compounds that absorb at 215 nm. Follow the HPLC software's manual to determine relative purity (in %) of the glycoprotein.
A glycoprotein sample to be analysed is directly obtained from a manufacturing batch. To identify and quantify the polysaccharide content of said sample, use a reference material prepared in advance as described above reflecting the same glycoprotein species, e.g. harbouring the same glycan structure on the same carrier protein.
The sample to be analysed can also contain multiple different glycoproteins, if the reference material used in the below mentioned protocol is identical in terms of composition and glycan structure.
If not otherwise mentioned, use MS grade chemicals to prepare eluents.
Note: The glycoprotein to be analysed does not need to be derivatised (e.g. via isotope labeling). Furthermore, no enzymatic treatments are needed, hence lengthy sample preparation before analysis is not required. The glycoprotein can be considered to be analysed in its native state as described above. Further, no internal standard for quantification is added to the sample but instead the generation of a separate calibration curve is sufficient.
1) Optionally perform a buffer exchange of the sample and the calibration reference standard material. This step may be desired to prevent certain matrix components entering the MS detector. However, it is likely that the buffer exchange also removes free polysaccharide fragments thereby prohibiting a correct determination of the free polysaccharide content within the said sample.
Instead it is recommended to use a divert valve between the LC and the MS system which can be programmed to divert undesired components into the waste after the elution from the liquid chromatography.
If performed, use centrifugal filters with an appropriate molecular weight cut off to exchange the buffer at least 3 times to eluent A (H2O MilliQ-grade, 0.1% v/v Formic acid). The amount of sample (e.g. 30 μg) depends on the glycoprotein of interest and must be optimized.
2) Prepare HPLC vials with the sample to be analysed and the reference material. Optimal concentrations depend on the used LC-MS system. To create a calibration curve, the different calibration points of the reference material can be adapted by either injecting the same volume of different prepared concentrations or by injecting different volumes of the same concentration. This depends on the LC system's injector linearity as well as on the sample to be analysed (e.g. potential interferences by adsorption to the vial over time, etc.) and must be optimized for the specific sample.
3) Prepare the LC-MS system. An ACQUITY-Synapt G2 HDMS from Waters, as an exemplary system, is prepared by calibrating the MS detector according to the manufacturer's manual with NaI. Use a suitable reverse phase column for your system (e.g. ACQUITY BEH300 C4, 1.7 μm 2.1×150 mm, Waters) capable of eluting your protein. Depending on the size of the glycoprotein to be analysed, a different carbon polymer length of the reverse phase material may be chosen (e.g. C8 or C18) to retain and elute the sample properly. Equilibrate the system with Eluent A (H2O MilliQ-grade, 0.1% v/v formic acid), and Eluent B (Acetonitrile, 0.1% v/v formic acid).
4) Sequentially inject the sample and the calibration points of the reference material. The following instrument method/gradient profile are suitable:
Depending on the targeted glycoprotein and the used system/column, these gradients as well as injection amounts may be adapted.
5) Analyse the eluted proteins with the attached detectors: Optionally, acquire UV absorbance signal at the desired wavelength. If UV absorbance signal is desired, larger amount of the sample may need to be injected and injection concentration must be optimized. Optionally, use a split/divert valve between the LC and the MS system to prevent oversaturating the MS detector.
Use the system's MS detector (e.g. quadrupole TOF Synapt G2 HDMS spectrometer, Waters) with electrospray ionization in positive resolution mode. Acquire data at the instruments optimized conditions. The following parameters were used on a TOF Synapt G2 HDMS spectrometer:
The critical parameter is the sampling cone voltage, resulting in in-source fragmentation of the glycan chain. Depending on the glycoprotein to be analysed, this cone voltage may need to be optimized.
6) Process acquired data. Data processing is performed by using the manufacturer's provided software packages (e.g. MassLynx, Waters). First, combine spectra across the main chromatographic peak (TIC MS function) which represents the eluted glycoprotein. If LC-MS acquisition parameters were optimized appropriately, the in-source fragmentation results in a highly specific mass peak originating from the polysaccharide chain(s) of the analysed glycoprotein. (c.f.
Second, for the next step use the extracted chromatograms of the identified specific mass peak: The area under the curve at the main chromatographic peak (representing the eluted glycoprotein) corresponds to the amount of injected bound polysaccharide of the reference material. With a calibration curve (polysaccharide amount vs. area under the curve; c.f.
Optionally, the extracted chromatograms of the identified specific mass peak can further be used to determine the relative amount of free polysaccharide: Compare the sum of the area under the curve of all but not the main chromatographic peak to the area under the curve of the main chromatographic peak (representing the eluted glycoprotein). Determination of free polysaccharides within the sample may further be optimized by extracting chromatograms for different fragments of the polysaccharide chain (e.g. mono-, disaccharide fragments, modified saccharides, polysaccharide-specific oxonium ions, etc).
Optionally, determine the degree of modification of the polysaccharide with the combined spectra across the chromatographic main peak (representing the eluted glycoprotein): In the example of O-Acetylated polysaccharide chains, the specific mass peak identified may have a neighbouring peak with a mass difference of 42 Da representing a de-acetylated form of the glycan (c.f.
Optionally, the acquired UV chromatogram and/or the TIC chromatogram can be used to determine the relative purity of the analysed sample: Compare the sum of the area under the curve of all but not the main chromatographic peak to the area under the curve of the main chromatographic peak (representing the eluted glycoprotein).
It is to be noted that for multivalent glycoconjugate vaccine (currently a 10-valent E. coli (ExPEC) vaccine is for instance under development, comprising 10 different E. coli O-antigen polysaccharides each independently covalently coupled to EPA carrier protein, i.e. containing 10 drug substances), the release of each of the individual drug substances before the present invention typically required several different assays, including a PS content assay (similar to step I.2 above), as well as subsequently (i.e., dependent on outcome of the PS content assay) free PS content assays (similar to step I.3 above) and for some serotypes an assay to determine O-Acetylation (similar to step I.4 above). This sequential dependency of two other assays leads to a low throughput during quality control (“QC”) release. In addition, identity and purity assays (similar to steps I.1 and I.5 above, respectively) also are typically to be performed for release of each drug substance.
One of the advantages of the methods of the invention is that these 5 different assays now can all be combined in one analytical procedure (section II above) where the only sample preparation is a dilution step, which can reduce the time required for QC testing chemical analysis from about two weeks down to about two days, resulting in a reduction of required time, materials and operators to obtain the same relevant information. Thus, the method results in significantly shortened batch release time at lower cost.
Moreover, the assay can be performed on individual drug substances, but also even after the individual drug substances have been mixed into a more complex drug product, e.g. on the final multivalent glycoconjugate vaccine composition.
Moreover, the high specificity of a spectrometric detector allows quantification in process intermediate samples where sample purity is generally much lower. This will reduce costs and time during process optimization and therefore reduce overall development costs of commercial manufactured glycoprotein-based vaccines.
| Number | Date | Country | Kind |
|---|---|---|---|
| 21154080.2 | Jan 2021 | EP | regional |
